OA13 Preliminary results from the National Axial Spondyloarthritis Society time to diagnosis audit: two years on

Le résumé fourni par la source

Abstract Background/Aims Time to diagnosis (TTD) is a worldwide problem in axial spondyloarthritis (axial SpA), with the UK faring worse than many other countries. Extended delays are associated with functional decline, poorer psychological well-being and higher healthcare costs. In June 2021, the National Axial Spondyloarthritis Society (NASS) launched the ‘Act on Axial SpA’ campaign in a bid to reduce the TTD to 12 months. A survey was created by NASS and UK rheumatology teams to explore the patient journey from symptom onset to diagnosis and to assess the national performance. Methods An online survey was launched in October 2022 for people newly diagnosed with axial SpA. The survey comprised 7 demographic questions and 6 questions pertaining to the patient journey to diagnosis. Hospital governance approval was sought locally and patient information leaflets, posters and QR codes were distributed in UK clinics. To reduce potential recall bias, only data from patients diagnosed between January 2021 and September 2024 were included in the analysis. Results Five hundred and fifty-three patients from 54 UK rheumatology departments were included: 46.7% female (n = 258), mean age at symptom onset 31.8 years (SD 12.67) and the mean age at diagnosis 39.9 years (SD 12.95). The mean and median total TTD were 8 years (SD 8.91) and 4.7 years (IQR 9.25), respectively. Table 1 shows the TTD data by year, stage of patient journey and gender. Conclusion Preliminary results from a UK-based audit may indicate a trend towards reduced TTD in axial SpA, seemingly due to quicker referral from primary care to rheumatology and faster assessment in rheumatology. Men experience a shorter TTD, however the improvement in TTD for women is greater between 2021 and 2024. A sustained, nationwide effort is paramount to build upon these positive signs and reduce the TTD in axial SpA in the UK. Disclosure T.A. Ingram: Other; Institutional grant funding from AbbVie, Biogen, Janssen, Lilly, Novartis and UCB. J. Eddison: Other; Institutional grant funding from AbbVie, Biogen, Janssen, Lilly, Novartis and UCB. A. Chan: Honoraria; A.C. has received speaker fees and travel support from Novartis, UCB, Lilly, AbbVie, Amgen, Medacs, and Janssen. M. Chan: Honoraria; M.C. has received honoraria and sponsorship from UCB, Novartis, AbbVie and Lilly. D. Das: None. J. Freeston: Consultancies; J.F. has received consultancy fees from Ferring. Honoraria; J.F. has received honoraria / speaking fees from UCB, Novartis, Janssen and Acindes. W.J. Gregory: Honoraria; W.G. has received honoraria for speaking and advisory board from AbbVie, Janssen, Novartis, Pfizer, Sobi and UCB. T. Gudu: None. J. Hamilton: Other; Institutional grant funding from AbbVie, Biogen, Janssen, Lilly, Novartis and UCB. C. Clark: Honoraria; Consulting/speaker fees from AbbVie, Novartis, Galapagos, Gilead and Bristol Myers Squibb. Other; Institutional grant funding from AbbVie, Biogen, Janssen, Lilly, Novartis and UCB. S. Bamford: None. H. Tahir: None. A. Moorthy: None. K. Gaffney: Shareholder/stock ownership; K.G. is a shareholder of Rheumatology Events. Honoraria; K.G. has received honoraria or consultancy fees from Novartis, AbbVie, UCB, Lilly and Pfizer. Member of speakers’ bureau; K.G. has participated in speaker’s bureau for Novartis, UCB, AbbVie and Lilly. Grants/research support; K.G. has obtained grant support from NASS, Versus Arthritis, AbbVie, Alfasigma, Pfizer, UCB, Novartis, Eli Lilly, Medacpharma, Celltrion, Janssen and Biogen. Other; K.G. has received meeting expenses from AbbVie, Lilly, Roche, Novartis, Pfizer and UCB. R. Sengupta: Honoraria; R.S. has received honoraria for speaking and attending advisory boards with Pfizer, AbbVie, Biogen, BMS, Lilly, Novartis and UCB. Grants/research support; R.S. has received grants from UCB, BMS, AbbVie and Novartis. Other; R.S. has been sponsored to attend regional, national and international meetings by UCB, AbbVie, Novartis and Lilly. D. Webb: Other; Institutional grant funding from AbbVie, Biogen, Janssen, Lilly, Novartis and UCB.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.